牛牛AI助理已提取核心訊息
Nikko Asset Management Americas, Inc. has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission, indicating a change in its holdings of CRISPR Therapeutics AG. As of December 31, 2023, Nikko Asset Management Americas, Inc. reported shared voting power over 3,050,548 common shares and shared dispositive power over 3,369,762 common shares, representing 4.24% of the company's class of securities. This filing, dated February 12, 2024, and signed by Chief Compliance Officer Gary L. Beckham, certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing also notes that the securities are beneficially owned by Nikko Asset Management Americas, Inc.'s parent holding companies, Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Co., Ltd.
Nikko Asset Management Americas, Inc. has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission, indicating a change in its holdings of CRISPR Therapeutics AG. As of December 31, 2023, Nikko Asset Management Americas, Inc. reported shared voting power over 3,050,548 common shares and shared dispositive power over 3,369,762 common shares, representing 4.24% of the company's class of securities. This filing, dated February 12, 2024, and signed by Chief Compliance Officer Gary L. Beckham, certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing also notes that the securities are beneficially owned by Nikko Asset Management Americas, Inc.'s parent holding companies, Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Co., Ltd.
日興資產管理美洲公司已向美國證券交易委員會提交了附表13G的修正案，表明其持有的CRISPR Therapeutics AG發生了變化。截至2023年12月31日，日興資產管理美洲公司報告了對3,050,548股普通股的共同投票權，對3,369,762股普通股共享處置權，佔公司證券類別的4.24％。這份日期爲2024年2月12日的文件由首席合規官加里·貝克漢姆簽署，證明這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。該文件還指出，這些證券由日興資產管理美洲公司實益持有。”的母控股公司三井住友信託控股公司和日興資產管理有限公司
日興資產管理美洲公司已向美國證券交易委員會提交了附表13G的修正案，表明其持有的CRISPR Therapeutics AG發生了變化。截至2023年12月31日，日興資產管理美洲公司報告了對3,050,548股普通股的共同投票權，對3,369,762股普通股共享處置權，佔公司證券類別的4.24％。這份日期爲2024年2月12日的文件由首席合規官加里·貝克漢姆簽署，證明這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。該文件還指出，這些證券由日興資產管理美洲公司實益持有。”的母控股公司三井住友信託控股公司和日興資產管理有限公司
有用
沒用